Registry-listed formulations

Argipressin · chembl:CHEMBL2108986

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

16 source entries across 14 studies. This list may not include all unresolved or historical entries.

  • arginine vasopressinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arginine vasopressinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arginine VasopressinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Vasopressin, ArginineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arginine vasopressinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Vasopressin, ArginineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Vasopressin, ArginineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Empressin 40 IE/2 ml koncentrat till infusionsvätska, lösningRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Intranasal Arginine VasopressinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arginine vasopressinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusionRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Empressin 40 I.U./2 ml concentrato per soluzione per infusioneRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Empressin 40 I.U./2 ml concentrato per soluzione per infusioneRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Reverpleg 40 U.I./2 ml solution à diluer pour perfusionRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusionRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Empressine 40 I.E./2ml, concentraat voor oplossing voor infusieRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
3(27%)
Results Posted
67%(4 trials)

Phase Distribution

Not Applicable
3
27%
Phase 1/2
1
9%
Phase 4
2
18%
Phase 2/3
3
27%
Phase 3
2
18%

Phase Distribution

0

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1/2Combined phases
1(9.1%)
Phase 2/3Combined phases
3(27.3%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

11

all time

Status Distribution
Active(3)
Completed(6)
Other(2)

Detailed Status

Completed6
Recruiting3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 1/21 (9.1%)
Phase 2/33 (27.3%)
Phase 32 (18.2%)
Phase 42 (18.2%)
N/A3 (27.3%)

Trials by Status

completed655%
recruiting327%
unknown218%

Recent Activity

3 active trials
Showing 5 of 11
recruitingphase_1_2

Vasopressin and Pain Perception in the Brain

NCT03446456
recruitingphase_3

Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

NCT07063680
recruitingphase_3

Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

NCT06344442
completedphase_4

Argipressin's Influence on Blood Loss During Hepatic Resection

NCT05293041
unknownnot_applicable

Common and Differentiated Representations Between Social Exclusion and Social Separation

NCT05920707
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03446456Phase 1/2

Vasopressin and Pain Perception in the Brain

Recruiting
NCT07063680Phase 3

Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

Recruiting
NCT06344442Phase 3

Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Recruiting
NCT05293041Phase 4

Argipressin's Influence on Blood Loss During Hepatic Resection

Completed
NCT05920707Not Applicable

Common and Differentiated Representations Between Social Exclusion and Social Separation

Unknown
NCT04935814Phase 4

Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation

Completed
NCT03640949Phase 2/3

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

Completed
NCT03088345Phase 2/3

Early Use of Vasopressin in Post-Fontan Management

Completed
NCT00795366Not Applicable

Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients

Completed
NCT01296269Not Applicable

Effects of Intranasal Oxytocin and Vasopressin on Social Behavior

Unknown
NCT00995839Phase 2/3

Terlipressin in Septic Shock: Effects on Microcirculation

Completed

All 11 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Protein
Total Trials
11

External References

ChEMBL
CHEMBL2108986

Names & Codes

Research Codes

CI-107